Beneficial treatment with leflunomide and hydroxychloroquine combination in Sjögren’s Disease

A significant reduction in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at week 24 was the successful primary outcome of the combination of leflunomide and hydroxychloroquine compared with placebo. Significant improvements were also seen in IgG, rheumatoid factor, and complement C4 levels. After positive results in a previous study (EudraCt2014-003140-12), the combination of leflunomide and hydroxychloroquine was now tested in the phase 2b, placebo-controlled RepurpSS-II trial (EudraCt: 2020-001933-11) over 24 weeks [1]. This 24-week trial included a subsequent single-arm crossover and 24-week open-label extension. Dr Wing-Yi Wong (University Medical Center Utrecht, the Netherlands) prese...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 18 June 20258 August 2025